Skip to main content

Tranexamic Acid

Tranexamic acid (TXA) is a synthetic lysine-analogue antifibrinolytic that reduces intraoperative blood loss and transfusion across urologic surgery, with a generally favorable thromboembolic-safety profile. For the reconstructive and pelvic surgeon the relevant questions are narrow: when does the blood-loss reduction justify giving it, and when is it dangerous? — and the answer to the second is uniquely urologic.[8][9]

Mechanism — and Why the Urinary Tract Is Special​

TXA competitively blocks the lysine-binding site on plasminogen, preventing its conversion to plasmin and thereby stabilizing fibrin clots.[3] The urinary tract is uniquely rich in plasminogen activators — urokinase and high urinary plasminogen drive local fibrinolysis and clot breakdown.[1][3] TXA's antifibrinolytic action directly counteracts this local fibrinolytic milieu, which is both why it is pharmacologically well-suited to urologic bleeding and why it carries a urology-specific hazard (clot retention in the upper tract — see Safety). TXA is renally excreted, so it concentrates exactly where the fibrinolysis is.[1][14]

Evidence Across Urologic Surgery​

The best general evidence is the POISE-3 urologic subanalysis (1,124 patients across laparoscopic/robotic, open, transurethral, and percutaneous procedures): TXA (1 g IV at incision and 1 g at closure) significantly reduced major bleeding (6.1% vs 9.5%; HR 0.63, 95% CI 0.41–0.97) with no significant thrombosis signal (HR 1.12, 0.79–1.58) and no interaction by surgical approach, cancer status, or antithrombotic use.[8] A meta-analysis of 13 RCTs (1,814 patients) across urologic surgery concurred: lower blood loss (SMD −0.705), reduced transfusion (OR 0.43), and no increased thromboembolic risk (OR 0.66).[9]

The procedure-specific trials that built this base — drawn largely from prostate, cystectomy, and stone surgery — are summarized here as the evidence the general recommendation rests on:

SettingKey finding
Prostate surgeryMeta-analysis (9 RCTs): reduced EBL (SMD −1.93) and transfusion (RR 0.61) without ↑ DVT/PE.[4] Landmark RRP RCT (n=200): transfusion 55% → 34% (NNT 5), no thromboembolism at 6 mo.[5] TURP benefit attributed to urokinase release from prostatic tissue.[2]
Radical cystectomyConflicting. The TACT RCT (n=344, weight-based protocol) found no transfusion reduction (37.0% vs 37.4%), hypothesized to reflect concurrent intraoperative heparin in 84%.[6] A propensity-matched series using a simplified 1 g bolus showed transfusion 47% → 19%.[7] The TXA–anticoagulation interaction is unresolved.
PCNLCochrane review (10 RCTs): systemic and topical TXA may reduce transfusion and improve stone-free rates, greatest benefit in higher-risk anatomy; probably no thromboembolic effect.[1]

Hematuria Management (Non-Surgical)​

Beyond the OR, TXA is used to control gross hematuria. A systematic review (7 studies, 970 participants) found it effective for both postoperative and non-postoperative hematuria, with route mattering:[10]

  • IV TXA performed best for postoperative hematuria;
  • oral and intravesical irrigation were more advantageous in non-surgical settings;
  • a pilot RCT of intravesical TXA for painless gross hematuria reduced irrigation-volume requirements (without a difference in hemoglobin decline).[11]

The upper-tract contraindication below applies with equal force to medical hematuria management.

Dosing​

Doses vary widely; confirm against institutional protocol.

SettingProtocol
General urologic surgery (POISE-3)1 g IV at surgery start + 1 g at end[8]
Radical prostatectomy500 mg IV load + 250 mg/h infusion intraop[5]
Radical cystectomy (TACT)10 mg/kg IV load + 5 mg/kg/h infusion intraop[6]
Radical cystectomy (simplified)1 g IV bolus preoperatively[7]
Post-prostatectomy hematuria10–15 mg/kg IV q8h → 20 mg/kg PO q8h until hematuria resolves[4]
Intravesical (hematuria)Local instillation via Foley during bladder irrigation[11]

Renal impairment requires dose reduction (renal excretion → accumulation).[14]

Safety and Contraindications​

Thromboembolism. Multiple meta-analyses and the POISE-3 subanalysis show no significant increase in VTE with TXA in urologic surgery.[8][9][4][12] The HALT-IT trial (GI bleeding) did detect a small but real VTE signal (0.8% vs 0.4%), so the risk is best described as real but small.[1]

Upper urinary tract bleeding — the critical urologic contraindication. TXA is traditionally contraindicated when the bleeding source is renal or ureteral: stabilized clots can be retained in the ureter and cause obstructive uropathy and potentially permanent renal injury.[14] A systematic review put the actual rate of obstructing urinary-tract clot at <1%, but it remains a standard contraindication and the single most important urology-specific caution.[15]

Other. Dose-dependent seizure risk above ~2 g/day;[1] in cancer surgery, a meta-analysis of 16 RCTs (1,830 patients) found reduced blood loss/transfusion with no increase in complications, reoperation, mortality, or stay.[16]

Guideline Status and Reconstructive Relevance​

Major urologic guidelines currently make no formal recommendation on TXA; adoption is variable, and the evidence best supports perioperative use when bleeding risk is high — and urologic surgery is itself classified high-bleeding-risk by NCCN in the anticoagulation-management context.[8][13] For the reconstructive and urogynecologic surgeon, TXA is a generalizable perioperative hemostatic adjunct for higher-blood-loss pelvic and vaginal work, complementary to local measures such as hydrodissection with a vasoconstrictor and energy vessel sealing — with the firm exception of suspected upper-tract bleeding.

See Also​

References​

1. Cleveland B, Norling B, Wang H, et al. Tranexamic acid for percutaneous nephrolithotomy. Cochrane Database Syst Rev. 2023;10:CD015122. doi:10.1002/14651858.CD015122.pub2

2. Vanderbruggen W, Brits T, Tilborghs S, Derickx K, De Wachter S. The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: a double-blind, randomized controlled trial. Prostate. 2023;83(16):1584–1590. doi:10.1002/pros.24616

3. Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245–253. doi:10.1056/NEJM199807233390407

4. Longo MA, Cavalheiro BT, de Oliveira Filho GR. Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery. J Clin Anesth. 2018;48:32–38. doi:10.1016/j.jclinane.2018.04.014

5. Crescenti A, Borghi G, Bignami E, et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ. 2011;343:d5701. doi:10.1136/bmj.d5701

6. Breau RH, Lavallée LT, Cagiannos I, et al. Tranexamic acid during radical cystectomy: a randomized clinical trial. JAMA Surg. 2024;159(12):1355–1363. doi:10.1001/jamasurg.2024.4183

7. Egen L, Keller K, Menold HS, et al. Tranexamic acid reduces perioperative blood transfusions following open radical cystectomy — a propensity-score matched analysis. World J Urol. 2024;42(1):477. doi:10.1007/s00345-024-05168-x

8. Tikkinen KAO, Marcucci M, Halme ALE, et al. Safety and efficacy of tranexamic acid in urologic surgery: results from the international, randomized, placebo-controlled POISE-3 trial. Eur Urol. 2026. doi:10.1016/j.eururo.2026.03.019

9. Lin YH, Lee KC, Hsu CC, Chen KT. Efficacy and safety of intravenous tranexamic acid in urologic surgery: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2023;102(25):e34146. doi:10.1097/MD.0000000000034146

10. Naseralallah L, Nasrallah D, Alsheikh R, Assami D, Boudaka R. Tranexamic acid for the management of hematuria: a systematic review. Urology. 2026;210:136–142. doi:10.1016/j.urology.2025.12.035

11. Moharamzadeh P, Ojaghihaghighi S, Amjadi M, Rahmani F, Farjamnia A. Effect of tranexamic acid on gross hematuria: a pilot randomized clinical trial study. Am J Emerg Med. 2017;35(12):1922–1925. doi:10.1016/j.ajem.2017.09.012

12. Fowler H, Law J, Tham SM, et al. Impact on blood loss and transfusion rates following administration of tranexamic acid in major oncological abdominal and pelvic surgery: a systematic review and meta-analysis. J Surg Oncol. 2022;126(3):609–621. doi:10.1002/jso.26900

13. National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease (NCCN Clinical Practice Guidelines in Oncology). 2026.

14. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47. doi:10.1111/j.1365-2516.2012.02909.x

15. Lee SG, Fralick J, Wallis CJD, et al. Systematic review of hematuria and acute renal failure with tranexamic acid. Eur J Haematol. 2022;108(6):510–517. doi:10.1111/ejh.13762

16. Soliman A, Azim AAA, Elgarawany A, et al. Efficacy and safety of tranexamic acid in solid cancer surgeries: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment. Ann Surg Oncol. 2026. doi:10.1245/s10434-026-19377-8